We don't need a lawyer running a drug company.
It's insanity to have this man as CEO.
I don't usually write about management but Merck's performance this year I lay at the CEO's door.
Spinning off the Animal Health and the Consumer Products businesses would be as Icahn often mentions (a no-brainer).
These divisions have no place in a drug company. That's MHO.
I hold 1000 shares of DVN and besides what I've read about XTXI and DVN merging some assets, I still don't get it.
Will DVN issue shares in the new spinoff?
Will we get shares in a MLP?
Will we get XTXI shares?
Or does anyone know yet how this will pan out?
Maybe someone smarter than me can answer these questions.